secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eikon Therapeutics, Inc. (EIKN)
CIK:        0001861123
Form:       8-K
Filed at:   2026-06-10T20:15:32+00:00
Accession:  0001193125-26-265861
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eikon Therapeutics appoints Ma. Fatima D. Francisco to Board as Class I director
--------------------------------------------------------------------------------

- Appointment effective June 15, 2026; serves until 2027 annual meeting.
- Annual retainer of $50,000 paid quarterly; initial option for 85,937 shares at $8.96.
- Option vests in 48 equal monthly installments subject to continued service.
- Ms. Francisco will serve on the Compensation Committee of the Board.
- No arrangements or related-person transactions with the Company disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526265861/0001193125-26-265861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861123/000119312526265861/eikn-20260605.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer